Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries

JAMA

Volumn 281, Issue 1, 1999, Pages 67-71

  Hanberger, Håkan ^a   Garcia Rodriguez, José Angel ^b   Gobernado, Miguel ^c   Goossens, Herman ^d   Nilsson, Lennart E ^a   Struelens, Marc J ^e  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM ISOLATION; BELGIUM; FRANCE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PORTUGAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; STRAIN DIFFERENCE; SWEDEN;

EID: 0033528076     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.1.67     Document Type: Article

References (25)

1. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA. 1995; 274:639-644.
2. Davin-Regli A, Monnet D, Saux P, et al. Molecular epidemiology of Enterobacter aerogenes acquisition: one year prospective study in two intensive care units. J Clin Microbiol. 1996;34:1474-1480.
3. Jarlier V, Fosse T, Philippon A, for the ICU Study Group. Antibiotic susceptibility in aerobic gramnegative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study). Intensive Care Med. 1996;22:1057-1065.
4. Verbist L. Incidence of multi-resistance in gram-negative bacterial isolates from intensive care units in Belgium: a surveillance study. Scand J Infect Dis. 1991; 78(suppl):45-53.
5. Shah PM, Asanger R, Kahan FM. Incidence of multi-resistance in gram-negative aerobes from intensive care units of 10 German hospitals. Scand J Infed Dis. 1991; 78(suppl):22-34.
6. Buirma RJA, Horrevorts AM, Wagenvoort JHT. Incidence of multi-resistant gram-negative isolates in eight Dutch hospitals. Scand J Infect Dis. 1991;78 (suppl):35-44.
7. Itokazu GS, Quinn JP, Bell-Dixon C, Kahan FM, Weinstein RA. Antimicrobial resistance rates among gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis. 1996; 23:779-784.
8. Glupczynski Y, Delmée M, Goossens H, Struelens M. A multicentre survey of antimicrobial resistance in gram-negative isolates from Belgian intensive care units in 1994-1995. Acta Clin Belg. 1998;53:28-38.
9. Hanberger H, Nilsson LE, and the Swedish ICU Study Group. High frequency of antibiotic resistance among gram-negative isolates in intensive care units at 10 Swedish hospitals. Clin Microbiol Infect. 1997;3: 208-215.
10. Burwen DR, Banerjee SN, Gaynes RP, and the National Nosocomial Infections Surveillance System. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis. 1994;170:1622-1625.
11. Emori TG, Culver DH, Horan TC, et al. National Nosocomial Infections Surveillance (NNIS) System: description of surveillance methodology. Am J Infect Control. 1991;19:19-35.
12. Brown DF, Brown L. Evaluation of the E test, a novel method of quantifying antimicrobial activity. J Antimicrob Chemother. 1991;27:185-190.
13. National Committee for Clinical Laboratory Standards (NCCLS). Minimum Inhibitory Concentration (MIC) Interpretive Standards M7-A4. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1997. Document 2.
14. Archibald L, Phillips L, Monnet D, McGowan JE, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis. 1997;24:211-215.
15. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995;8:557-584.
16. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585-590.
17. Philippon A, Labia R, Jacoby G. Extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1989;33:1131-1136.
18. Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp from intensive care units in Europe. J Antimicrob Chemother. 1996;38:409-424.
19. Tilley PAG, Roberts FJ. Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin Infect Dis. 1994;18:896-900.
20. Cisneros JM, Reyes MJ, Pachón J, et al. Bacteremia due to Acinetobader baumannii: epidemiology, clinical findings and prognostic features. Clin Infect Dis. 1996;22:1026-1032.
21. Riley TV, Webb SA, Cadwallader H, Briggs BD, Christiansen L, Bowman RA. Outbreak of gentamicin-resistant Acinetobacter baumanii in an intensive care unit: clinical, epidemiologic and microbiological features. Pathology. 1996;28:359-363.
22. Goetz A, Yu VL. The intensive care unit: the hot-test zone. Curr Opin Infect Dis. 1997;10:319-323.
23. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993;119:353-358.
24. Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. Clin Infect Dis. 1995;21:1107-1113.
25. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA. 1996;275:234-240.